HomeTrialNCT07402876
🔬NCT07402876Phase 3RECRUITING

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Study Summary

A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma

View on ClinicalTrials.gov ↗
Study Details
Enrollment20 participants
Primary Completion
Lead SponsorAldeyra Therapeutics, Inc.
Data Retrieved2026-04-11 02:53:10.962452+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.